Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

patient advocate

Add ILCN as a preferred source

October 15, 2021

Toward More Inclusive, Accessible Clinical Trial Consent Forms

Patient Advocacy

It is a trend many years in the making, but the time is ripe to fix the increasing problems with clinical trial consent documentation. The word count and complexity of mandated information in informed consent forms have been multiplying, but their value remains dubious. In 2016, Danish researchers studying consent forms found that “a considerable…
December 10, 2019

STARS Patient Research Advocate Training Program Seeks Patients and Caregivers

Patient Advocacy & Survivorship

By Adam Mohrbacher Posted: December 11, 2019 Patients with lung cancer and their caregivers are becoming more empowered and knowledgeable than ever. As a result, lung cancer now has a growing group of patients who have lived long enough to become advocates for their disease. Some are evolving into research advocates— volunteers with a personal…
December 10, 2019

From Patient to Patient Research Advocate: The STARS Journey

Patient Advocacy & Survivorship

By Adam Mohrbacher Posted: December 11, 2019 With the rise of organized lung cancer patient advocacy groups,1 patients, advocates, and caregivers are now playing a larger role than ever in raising awareness, providing education, and even driving research into the disease. In order to support this groundswell of passion and advocacy, the IASLC’s Supportive Training…

patient advocate

Toward More Inclusive, Accessible Clinical Trial Consent Forms

STARS Patient Research Advocate Training Program Seeks Patients and Caregivers

From Patient to Patient Research Advocate: The STARS Journey

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

No “Known” Risk Factors: The Health Consequences of Radiation Therapy

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

A Holistic Approach to Patient Care